Which insulin is ordered to be administered IV in a clinical scenario?

Which insulin is ordered to be administered IV in a clinical scenario?

• A. Insulin glargine
• B. Insulin Aspart
• C. Humulin regular insulin
• D. Detemir

Answer: (C)

Humulin regular insulin is the type of insulin that is specifically indicated for intravenous (IV) administration. This is due to its chemical structure and the pharmacokinetics that allow it to be rapidly absorbed and act quickly when given directly into the bloodstream. Regular insulin, being a short-acting insulin, is effective in managing acute hyperglycemia and is typically utilized in critical care settings, such as in patients with diabetic ketoacidosis or those requiring tight glucose control during surgery. In contrast, insulin glargine and detemir are long-acting insulins designed for subcutaneous use, providing a steady release of insulin over an extended period. These insulins are not suitable for IV administration as they do not act quickly enough and are designed for basal insulin control rather than acute correction of blood glucose levels. Insulin aspart, while a rapid-acting insulin that can be given subcutaneously and may also be used in continuous IV infusions in some protocols, is not the standard choice for initial IV bolus administration compared to regular insulin. Thus, Humulin regular insulin stands out as the correct option for IV delivery in a clinical scenario.

Humulin regular insulin is the type of insulin that is specifically indicated for intravenous (IV) administration. This is due to its chemical structure and the pharmacokinetics that allow it to be rapidly absorbed and act quickly when given directly into the bloodstream. Regular insulin, being a short-acting insulin, is effective in managing acute hyperglycemia and is typically utilized in critical care settings, such as in patients with diabetic ketoacidosis or those requiring tight glucose control during surgery.

In contrast, insulin glargine and detemir are long-acting insulins designed for subcutaneous use, providing a steady release of insulin over an extended period. These insulins are not suitable for IV administration as they do not act quickly enough and are designed for basal insulin control rather than acute correction of blood glucose levels. Insulin aspart, while a rapid-acting insulin that can be given subcutaneously and may also be used in continuous IV infusions in some protocols, is not the standard choice for initial IV bolus administration compared to regular insulin. Thus, Humulin regular insulin stands out as the correct option for IV delivery in a clinical scenario.